Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
出版年份 2016 全文链接
标题
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
作者
关键词
SGLT2 inhibitors, Cardiovascular, Type 2 diabetes, Dapagliflozin, Cardiovascular risk, Major adverse cardiovascular events, Meta-analysis
出版物
Cardiovascular Diabetology
Volume 15, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-02-19
DOI
10.1186/s12933-016-0356-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade
- (2015) Michael A. Weber et al. BLOOD PRESSURE
- Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
- (2015) Paola Fioretto et al. Cardiovascular Diabetology
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
- (2015) William T. Cefalu et al. DIABETES CARE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
- (2014) Bowen Lin et al. Cardiovascular Diabetology
- Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
- (2014) Linong Ji et al. CLINICAL THERAPEUTICS
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- 8. Cardiovascular Disease and Risk Management
- (2014) DIABETES CARE
- Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise
- (2014) K. Kaku et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 28-Week Extension
- (2014) Lawrence A. Leiter et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
- (2014) Rury R Holman et al. LANCET
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
- (2013) Steven P. Marso et al. AMERICAN HEART JOURNAL
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
- (2013) Bruce Neal et al. AMERICAN HEART JOURNAL
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum
- (2013) I. Raz et al. DIABETES CARE
- Glycemic Variability: Both Sides of the Story
- (2013) A. Ceriello et al. DIABETES CARE
- Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations
- (2013) B. Hirshberg et al. DIABETES CARE
- Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes
- (2013) L. Shi et al. DIABETES CARE
- The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
- (2013) S. Stark Casagrande et al. DIABETES CARE
- Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
- (2013) Serge A. Jabbour et al. DIABETES CARE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
- (2013) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
- (2013) Sunder Mudaliar et al. Diabetes Technology & Therapeutics
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2013) Mei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
- (2013) et al. EUROPEAN HEART JOURNAL
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis
- (2013) A. Goto et al. BMJ-British Medical Journal
- Variation of Fasting Plasma Glucose: A Predictor of Mortality in Patients with Type 2 Diabetes
- (2012) Cheng-Chieh Lin et al. AMERICAN JOURNAL OF MEDICINE
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range
- (2012) C. J. Bailey et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial
- (2012) K. Kaku et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Postprandial Hyperglycemia and Glycemic Variability: Should we care?
- (2011) E. Standl et al. DIABETES CARE
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus
- (2011) James H. O'Keefe et al. MAYO CLINIC PROCEEDINGS
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Severe Hypoglycemia and Risks of Vascular Events and Death
- (2010) Sophia Zoungas et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) E. Mannucci et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started